Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENSIFY MDD: Intensified Pharmacological Treatment for Major Depressive Disorder
NCT05973851Phase 3Recruiting
- Start
- Aug 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of esketamine and ketamine in major depressive disorder (MDD) (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 6 weeks. Started Aug 2024; status: recruiting.
02
Drugs
esketamineketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05973851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05973851.